Literature DB >> 28920156

Cancer risk in the EMPA-REG OUTCOME trial. Reply to Shaikh AMY [letter] and Kohler S, Lee J, George JT et al [letter].

Huilin Tang1, Jiali Han2,3, Yiqing Song4.   

Abstract

Entities:  

Keywords:  Bladder cancer; Empagliflozin; SGLT2 inhibitors

Mesh：

Substances：

Year:  2017        PMID： 28920156     DOI： 10.1007/s00125-017-4431-z

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  4 in total

1.  SGLT2 inhibitors and cancer: why further evidence is required.

Authors:  Altamash M Y Shaikh
Journal:  Diabetologia       Date:  2017-09-13       Impact factor: 10.122

2.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

Review 3.  SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Huilin Tang; Qi Dai; Weilong Shi; Suodi Zhai; Yiqing Song; Jiali Han
Journal:  Diabetologia       Date:  2017-07-19       Impact factor: 10.122

4.  Bladder cancer in the EMPA-REG OUTCOME trial.

Authors:  Sven Kohler; Jisoo Lee; Jyothis T George; Silvio E Inzucchi; Bernard Zinman
Journal:  Diabetologia       Date:  2017-09-14       Impact factor: 10.122
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.